Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.52 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.45 |
| ▸ | ABAT | P80404 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238844 | 0.85 | ALDH1A1 (0.51) | ALDH1A1ALDH1A3TSHRTRIM24HPGD | |
| SCHEMBL14670073 | 0.80 | ALDH1A1 (0.48) | ALDH1A1ALDH1A3HPGDMAPTKDM4E | |
| SCHEMBL3750278 | 0.78 | NR4A1 (0.58) | ALDH1A1TSHRMAPTKDM4EMEN1 | |
| SCHEMBL2480440 | 0.76 | HTT (0.49) | ALDH1A1TDP1MAPTMEN1KMT2A | |
| SCHEMBL4082746 | 0.75 | ALDH1A1 (0.59) | ALDH1A1ALDH1A3TSHRTRIM24HPGD | |
| SCHEMBL4082889 | 0.73 | ALDH1A1 (0.54) | ALDH1A1ALDH1A3TSHRTRIM24HPGD | |
| SCHEMBL1239502 | 0.73 | CYP11B1 (0.56) | ALDH1A1ALDH1A3TSHRTRIM24HPGD | |
| SCHEMBL4082710 | 0.72 | ALDH1A1 (0.52) | ALDH1A1ALDH1A3TSHRTRIM24HPGD | |
| SCHEMBL758550 | 0.72 | PSEN1 (0.57) | ALDH1A1ALDH1A3 | |
| SCHEMBL29940580 | 0.72 | PSEN1 (0.57) | ALDH1A1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2261218-B1 | Imidazole compound for use as an intermediate in the production of cinnamide compounds | EISAI R&D MAN CO LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-20110086860-A1 | COMPOUND | KIMURA TEIJI | 2011-04-14 | — | — | US | disclosed |
| US-7923563-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| EP-1808432-B1 | AMORPHOUS FORM OF CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-7667041-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-20090203916-A1 | Amorphous object of cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090048448-A1 | SALTS OF CYNNAMIDE COMPOUND OR SOLVATES THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1953151-A1 | SALTS OF CYNNAMIDE COMPOUND OR SOLVATES THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1808432-A1 | AMORPHOUS OBJECT OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-07-18 | — | — | EP | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060241038-A1 | Therapeutic agent for Abeta related disorders | EISAI CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006112552-A2 | THERAPEUTIC AGENTS FOR ABETA RELATED DISORDERS | EISAI CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086860-A1 | COMPOUND | ARRB1, NR3C2, ADRA2C | ALDH1A1 149/4885ALDH1A3 1112/4885TSHR 2476/4885 |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | ALDH1A1 451/4885ALDH1A3 1638/4885TSHR 4695/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | ALDH1A1 58/4885ALDH1A3 366/4885TSHR 3629/4885 |
| US-20060241038-A1 | Therapeutic agent for Abeta related disorders | APP, BACE1, PSEN1 | ALDH1A1 2978/4885ALDH1A3 3516/4885TSHR 4455/4885 |
| US-20090048448-A1 | SALTS OF CYNNAMIDE COMPOUND OR SOLVATES THEREOF | APP, BACE1, BACE2 | ALDH1A1 2955/4885ALDH1A3 3676/4885TSHR 4635/4885 |
| US-20090203916-A1 | Amorphous object of cinnamide compound | BACE1, APP, PSEN1 | ALDH1A1 442/4885ALDH1A3 2871/4885TSHR 4763/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | ALDH1A1 1375/4885ALDH1A3 3866/4885TSHR 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.